Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHE NASDAQ:BHST NASDAQ:HYPD NASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.66+2.6%$4.69$2.66▼$6.03$41.37M0.2520,121 shs3,886 shsBHSTBioHarvest Sciences$2.03+5.7%$3.09$1.82▼$12.80$37.66M0.8744,082 shs137,381 shsHYPDHyperion DeFi$2.56+2.0%$3.17$2.49▼$15.00$38.05M2.49260,868 shs108,963 shsXCURExicure$1.75-0.6%$2.37$1.43▼$9.48$11.22M3.611.19 million shs19,007 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics+2.64%-1.69%-4.80%+1.75%-28.85%BHSTBioHarvest Sciences+5.73%-25.09%-27.63%-52.79%-73.22%HYPDHyperion DeFi+1.99%-5.88%-15.37%-39.91%-66.75%XCURExicure-0.57%-7.41%-27.08%-49.57%-77.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.66+2.6%$4.69$2.66▼$6.03$41.37M0.2520,121 shs3,886 shsBHSTBioHarvest Sciences$2.03+5.7%$3.09$1.82▼$12.80$37.66M0.8744,082 shs137,381 shsHYPDHyperion DeFi$2.56+2.0%$3.17$2.49▼$15.00$38.05M2.49260,868 shs108,963 shsXCURExicure$1.75-0.6%$2.37$1.43▼$9.48$11.22M3.611.19 million shs19,007 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics+2.64%-1.69%-4.80%+1.75%-28.85%BHSTBioHarvest Sciences+5.73%-25.09%-27.63%-52.79%-73.22%HYPDHyperion DeFi+1.99%-5.88%-15.37%-39.91%-66.75%XCURExicure-0.57%-7.41%-27.08%-49.57%-77.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.40Hold$13.00178.97% UpsideBHSTBioHarvest Sciences 2.00Hold$10.00392.61% UpsideHYPDHyperion DeFi 2.25Hold$6.95171.48% UpsideXCURExicure 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest XCUR, BHST, HYPD, and ATHE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026ATHEAlterity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/14/2026HYPDHyperion DeFi Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/1/2026HYPDHyperion DeFi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $6.606/30/2026ATHEAlterity Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/24/2026HYPDHyperion DeFi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/18/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/17/2026ATHEAlterity Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/16/2026ATHEAlterity Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.006/11/2026XCURExicure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/8/2026HYPDHyperion DeFi Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.25 ➝ $7.306/3/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/ABHSTBioHarvest Sciences$34.51M1.15N/AN/A$1.30 per share1.56HYPDHyperion DeFi$1.04M37.20N/AN/A$4.73 per share0.54XCURExicure$500K22.30N/AN/A$0.62 per share2.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$7.87MN/AN/AN/AN/AN/AN/AN/A8/28/2026 (Estimated)BHSTBioHarvest Sciences-$11.14M-$0.59N/AN/AN/A-32.54%-76.03%-25.30%8/10/2026 (Estimated)HYPDHyperion DeFi-$45.31M-$9.95N/A2.23N/AN/A-91.59%-73.08%N/AXCURExicure-$4.95M-$1.55N/AN/AN/AN/A-179.41%-64.37%8/7/2026 (Estimated)Latest XCUR, BHST, HYPD, and ATHE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026BHSTBioHarvest Sciences-$0.13N/AN/AN/A$9.45 millionN/A5/29/2026Q1 2026XCURExicure-$18.60-$0.29+$18.31-$0.29$1.64 millionN/A5/14/2026Q1 2026BHSTBioHarvest Sciences-$0.13-$0.11+$0.02-$0.11$8.50 million$8.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/ABHSTBioHarvest SciencesN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A21.97N/ABHSTBioHarvest Sciences0.032.962.44HYPDHyperion DeFi0.121.971.97XCURExicureN/A0.790.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%BHSTBioHarvest SciencesN/AHYPDHyperion DeFi25.84%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%BHSTBioHarvest SciencesN/AHYPDHyperion DeFi7.50%XCURExicure52.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableBHSTBioHarvest SciencesN/A19.62 millionN/AN/AHYPDHyperion DeFi4015.16 million14.02 millionNo DataXCURExicure506.37 million3.01 millionNot OptionableXCUR, BHST, HYPD, and ATHE HeadlinesRecent News About These CompaniesExicure Inc (NASDAQ: XCUR) - Share Price and ResearchJuly 15, 2026 | intelligentinvestor.com.auIExicure Reaches Preliminary Settlement in Derivative LawsuitsJuly 9, 2026 | theglobeandmail.comExicure Announces Board and Committee ChangesJune 30, 2026 | globenewswire.comExicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementJune 11, 2026 | finanznachrichten.deExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementJune 10, 2026 | markets.businessinsider.comExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementJune 10, 2026 | globenewswire.comExicure Regains Nasdaq Compliance After Late Quarterly FilingJune 1, 2026 | tipranks.comExicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-QJune 1, 2026 | globenewswire.comExicure delays quarterly filing, trims quarterly lossMay 15, 2026 | tipranks.comExicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination TherapiesApril 22, 2026 | quiverquant.comQExicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)April 22, 2026 | globenewswire.comExicure Inc.April 13, 2026 | barrons.comExicure Strengthens Leadership With New COO and DirectorApril 10, 2026 | tipranks.comSummary Notice of Pendency and Proposed Settlement of Stockholder Derivative ActionsApril 2, 2026 | globenewswire.comExicure, Inc. Reports 2025 Financial Results and Announces Need for Additional FinancingMarch 25, 2026 | quiverquant.comQExicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional FinancingMarch 25, 2026 | quiverquant.comQExicure, Inc. Reports Full Year 2025 Financial ResultsMarch 25, 2026 | globenewswire.comExicure, Inc. Reports Full Year 2025 Financial ResultsMarch 25, 2026 | globenewswire.comExicure, Inc. Publishes Phase 2 Study Results for Burixafor, a Novel CXCR4 Inhibitor in Hematologic Disease TreatmentFebruary 5, 2026 | quiverquant.comQExicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing TransplantFebruary 5, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXCUR, BHST, HYPD, and ATHE Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$4.66 +0.12 (+2.64%) Closing price 07/27/2026 03:59 PM EasternExtended Trading$4.63 -0.03 (-0.67%) As of 07:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.BioHarvest Sciences NASDAQ:BHST$2.03 +0.11 (+5.73%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$2.06 +0.03 (+1.48%) As of 07:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Hyperion DeFi NASDAQ:HYPD$2.56 +0.05 (+1.99%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$2.56 +0.00 (+0.20%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Exicure NASDAQ:XCUR$1.75 -0.01 (-0.57%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$1.72 -0.03 (-1.71%) As of 07:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now AMD’s AI Bubble Could Burst Into Explosive Upside Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? A $1.5 Billion Wake-Up Call for Every AI Company on Wall Street AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Apple’s Earnings Setup Puts Its Record Rally and AI Patience to the Test Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
